PDF(Pubmed)
Abstract：
UNASSIGNED: Endocrine therapy (ET) adherence leads to increased survival in breast cancer (BC). How follow-up should be done to maximize adherence is not known.
UNASSIGNED: To assess adherence to ET, factors favouring adherence to ET and effects on survival in a population-based cohort of BC patients in western Sweden.
UNASSIGNED: This is a retrospective study.
UNASSIGNED: We included 358 patients operated for oestrogen receptor-positive BC and recommended 5 years of ET, in Region Halland, Sweden, year 2015 to 2016. Demographical, clinical and pathological data and use of ET were retrieved from the electronic medical records. Patients were considered adherent if taking ET for 5 years or during the full extent of the follow-up, until termination of ET due to BC relapse or death and where renewals of prescriptions of ET covered ⩾80% of the ordinated dose. Two follow-up routines were employed, ie, routine A where patients were contacted annually by nurses and a more passive follow-up routine B where patients were only contacted by nurses at 2 years and 5 years following start of ET.
UNASSIGNED: Medication persistence for 4 years and more was good and similar between patients initiating aromatase inhibitor (AI) and tamoxifen (75.7% and 72.0%, respectively, P = .43). More patients initiating AIs changed ET due to side effects compared with patients initiating tamoxifen (24.3% vs 9.9%, respectively, P < .0001). Endocrine therapy adherence was better for follow-up routine B than for follow-up routine A (hazard ratio [HR] = 2.71 [1.44-5.09], P = .0027).
UNASSIGNED: Adherence to ET in BC is high in Western Sweden. Less regular nurse-initiated contacts between BC patients and nursesled surprisingly to a better adherence than a more regular nurse-initiated contact.
Follow-up routines are important for adherence to anti-hormonal therapy after breast cancer surgery In this study conducted in western Sweden, researchers looked at how well breast cancer (BC) patients followed their prescribed endocrine therapy (ET) for 5 years, which is crucial for their survival. They studied 358 patients diagnosed with oestrogen receptor-positive BC between 2015 and 2016. The study compared two follow-up routines: one where patients were contacted annually by nurses (routine A) and another where patients were contacted only at 2 years and 5 years after starting ET (routine B). Surprisingly, patients in routine B, with less frequent nurse contacts, were more likely to adhere with their ET compared with those in routine A. The study also found that patients taking aromatase inhibitors (AIs) were more likely to switch their ET due to side effects compared with those taking tamoxifen, but overall, adherence rates were similar between the 2 groups. In summary, the study showed that BC patients in western Sweden generally followed their prescribed ET well. In addition, having less frequent nurse-initiated contacts surprisingly improved patient adherence with their treatment.
UNASSIGNED: To assess adherence to ET, factors favouring adherence to ET and effects on survival in a population-based cohort of BC patients in western Sweden.
UNASSIGNED: This is a retrospective study.
UNASSIGNED: We included 358 patients operated for oestrogen receptor-positive BC and recommended 5 years of ET, in Region Halland, Sweden, year 2015 to 2016. Demographical, clinical and pathological data and use of ET were retrieved from the electronic medical records. Patients were considered adherent if taking ET for 5 years or during the full extent of the follow-up, until termination of ET due to BC relapse or death and where renewals of prescriptions of ET covered ⩾80% of the ordinated dose. Two follow-up routines were employed, ie, routine A where patients were contacted annually by nurses and a more passive follow-up routine B where patients were only contacted by nurses at 2 years and 5 years following start of ET.
UNASSIGNED: Medication persistence for 4 years and more was good and similar between patients initiating aromatase inhibitor (AI) and tamoxifen (75.7% and 72.0%, respectively, P = .43). More patients initiating AIs changed ET due to side effects compared with patients initiating tamoxifen (24.3% vs 9.9%, respectively, P < .0001). Endocrine therapy adherence was better for follow-up routine B than for follow-up routine A (hazard ratio [HR] = 2.71 [1.44-5.09], P = .0027).
UNASSIGNED: Adherence to ET in BC is high in Western Sweden. Less regular nurse-initiated contacts between BC patients and nursesled surprisingly to a better adherence than a more regular nurse-initiated contact.
Follow-up routines are important for adherence to anti-hormonal therapy after breast cancer surgery In this study conducted in western Sweden, researchers looked at how well breast cancer (BC) patients followed their prescribed endocrine therapy (ET) for 5 years, which is crucial for their survival. They studied 358 patients diagnosed with oestrogen receptor-positive BC between 2015 and 2016. The study compared two follow-up routines: one where patients were contacted annually by nurses (routine A) and another where patients were contacted only at 2 years and 5 years after starting ET (routine B). Surprisingly, patients in routine B, with less frequent nurse contacts, were more likely to adhere with their ET compared with those in routine A. The study also found that patients taking aromatase inhibitors (AIs) were more likely to switch their ET due to side effects compared with those taking tamoxifen, but overall, adherence rates were similar between the 2 groups. In summary, the study showed that BC patients in western Sweden generally followed their prescribed ET well. In addition, having less frequent nurse-initiated contacts surprisingly improved patient adherence with their treatment.
摘要：
■内分泌治疗（ET）的依从性导致乳腺癌（BC）的生存率增加。如何进行随访以最大程度地坚持尚不清楚。
■为了评估对ET的依从性，在瑞典西部以人群为基础的BC患者队列中,有利于ET依从性的因素和对生存率的影响.
■这是一项回顾性研究。
■我们纳入了358例雌激素受体阳性BC患者，并推荐5年ET，在哈兰地区，瑞典,2015年至2016年。人口统计,从电子病历中检索临床和病理数据以及ET的使用。如果服用ET5年或在整个随访期间，患者被认为是粘附的，直到由于BC复发或死亡而终止ET，并且ET处方的更新涵盖了80％的指定剂量。采用了两个后续程序，ie,常规A，其中每年由护士联系患者，而更为被动的随访常规B，其中仅在ET开始后2年和5年由护士联系患者。
■服用芳香化酶抑制剂（AI）和他莫昔芬的患者持续用药4年以上效果良好，相似（75.7%和72.0%，分别,P=.43）。与开始他莫昔芬的患者相比，更多的患者因副作用而改变了ET（24.3％vs9.9％，分别,P<.0001)。随访常规B的内分泌治疗依从性优于随访常规A（风险比[HR]=2.71[1.44-5.09]，P=.0027）。
■在瑞典西部，对不列颠哥伦比亚省ET的依从性很高。与更常规的护士发起的接触相比，BC患者与护士之间的常规接触较少，令人惊讶的是，依从性更好。
在瑞典西部进行的这项研究中，随访程序对于乳腺癌手术后坚持抗激素治疗很重要，研究人员观察了乳腺癌（BC）患者在5年内遵循其处方内分泌治疗（ET）的情况，这对他们的生存至关重要。他们研究了2015年至2016年间诊断为雌激素受体阳性BC的358例患者。该研究比较了两种随访程序：一种是护士每年与患者联系（常规A），另一种是仅在开始ET后2年和5年与患者联系（常规B）。令人惊讶的是,常规B的患者，护士接触不太频繁，与常规A相比，服用芳香化酶抑制剂（AI）的患者更有可能因副作用而改变ET，但总的来说,两组的依从率相似.总之,研究表明，瑞典西部的BC患者通常遵循处方ET。此外,护士发起的接触频率较低，患者对治疗的依从性令人惊讶地提高。
■为了评估对ET的依从性，在瑞典西部以人群为基础的BC患者队列中,有利于ET依从性的因素和对生存率的影响.
■这是一项回顾性研究。
■我们纳入了358例雌激素受体阳性BC患者，并推荐5年ET，在哈兰地区，瑞典,2015年至2016年。人口统计,从电子病历中检索临床和病理数据以及ET的使用。如果服用ET5年或在整个随访期间，患者被认为是粘附的，直到由于BC复发或死亡而终止ET，并且ET处方的更新涵盖了80％的指定剂量。采用了两个后续程序，ie,常规A，其中每年由护士联系患者，而更为被动的随访常规B，其中仅在ET开始后2年和5年由护士联系患者。
■服用芳香化酶抑制剂（AI）和他莫昔芬的患者持续用药4年以上效果良好，相似（75.7%和72.0%，分别,P=.43）。与开始他莫昔芬的患者相比，更多的患者因副作用而改变了ET（24.3％vs9.9％，分别,P<.0001)。随访常规B的内分泌治疗依从性优于随访常规A（风险比[HR]=2.71[1.44-5.09]，P=.0027）。
■在瑞典西部，对不列颠哥伦比亚省ET的依从性很高。与更常规的护士发起的接触相比，BC患者与护士之间的常规接触较少，令人惊讶的是，依从性更好。
在瑞典西部进行的这项研究中，随访程序对于乳腺癌手术后坚持抗激素治疗很重要，研究人员观察了乳腺癌（BC）患者在5年内遵循其处方内分泌治疗（ET）的情况，这对他们的生存至关重要。他们研究了2015年至2016年间诊断为雌激素受体阳性BC的358例患者。该研究比较了两种随访程序：一种是护士每年与患者联系（常规A），另一种是仅在开始ET后2年和5年与患者联系（常规B）。令人惊讶的是,常规B的患者，护士接触不太频繁，与常规A相比，服用芳香化酶抑制剂（AI）的患者更有可能因副作用而改变ET，但总的来说,两组的依从率相似.总之,研究表明，瑞典西部的BC患者通常遵循处方ET。此外,护士发起的接触频率较低，患者对治疗的依从性令人惊讶地提高。
